Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Myrexis Inc. (MYRX : OTC)
 
 • Company Description   
Myrexis, Inc., formerly known as Myriad Pharmaceuticals, Inc., is a biotechnology company focused on discovering, developing, and commercializing novel therapies for the treatment of cancer. The Company's product pipeline includes Azixa (verubulin, MPC-6827), a microtubule destabilizer for brain cancer; MPC-3100, an HSP90 inhibitor for cancer; MPC-9528, a Cancer Metabolism Inhibitor; MPI-485520, an IKK inhibitor for cancer and inflammation; and others. Myriad Pharmaceuticals, Inc. is based in Salt Lake City, Utah.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.00 Daily Weekly Monthly
20 Day Moving Average: 51,531 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: 0.64
52 Week High: $0.01
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -96.97% -97.10%
12 Week -97.14% -97.67%
Year To Date -97.14% -97.29%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
C/O XSTELOS HOLDINGS INC. 630 FIFTH AVENUE SUITE 2260
-
NEW YORK,NY 10020
USA		 ph: 801-214-7800
fax: 801-214-7992		 investor.relations@myrexis.com http://www.myrexis.com
 
 • General Corporate Information   
Officers
Jonathan M. Couchman - Chairman of the Board
Steven D. Scheiwe - Director
Michael C. Pearce - Director
John T. Henderson, M.D. - Director
Dennis H. Langer, M.D., J.D. - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 62856H107
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 0.64
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - -
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©